Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of T Cell Engaging Bi/Tri-specific Antibodies in Subjects With MM

NCT06892522 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06892522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06892522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of T Cell Engaging Bi/Tri-specific Antibodies in Subjects With MM
Lead sponsor
AbbVie
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 30, 2025
Completion date
December 31, 2035
Enrollment
602 (estimated)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma